MedTrace Logo

Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C

NCT00040729 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2015-04-28

No results posted yet for this study

Summary

RATIONALE: Genetic testing for a specific enzyme may help doctors determine whether side effects from or response to chemotherapy are related to a person's genetic makeup.

PURPOSE: Genetic trial to determine whether different forms of the UGT1A1 gene are related to the body's ability to break down drugs and to the gastrointestinal side effects seen in patients previously treated with flavopiridol.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

GENETIC

mutation analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • William D. Figg, PharmD · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00040729 on ClinicalTrials.gov